Incidence, Timing, and Management of Infections in Patients Receiving Daratumumab for the Treatment of Newly Diagnosed Transplant-Ineligible Multiple Myeloma in the MAIA Study

被引：0

作者：

Bahlis, Nizar J. ^{[1
]}

Facon, Thierry ^{[2
,3
]}

Usmani, Saad ^{[4
]}

Moreau, Philippe ^{[5
]}

Raje, Noopur ^{[6
]}

Zweegman, Sonja ^{[7
]}

Chari, Ajai ^{[8
]}

Perrot, Aurore ^{[9
]}

Manier, Salomon ^{[10
]}

Orlowski, Robert ^{[11
]}

Goldschmidt, Hartmut ^{[12
]}

Basu, Supratik ^{[13
,14
]}

Hulin, Cyrille ^{[15
]}

Weisel, Katja ^{[16
]}

Mohty, Mohamad ^{[17
,18
]}

Plesner, Torben ^{[19
,20
]}

Cook, Gordon ^{[21
]}

Leleu, Xavier ^{[22
]}

Quach, Hang ^{[23
]}

Venner, Christopher P. ^{[24
]}

Ngo, Mai ^{[25
]}

Bolyard, Kasey ^{[25
]}

Carson, Robin ^{[25
]}

Borgsten, Fredrik ^{[25
]}

Kumar, Shaji ^{[25
,26
]}

机构：

[1] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[2] Univ Lille, & French Acad Med, Dept Haematol, Paris, France

[3] French Acad Med, Paris, France

[4] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA

[5] Univ Hosp Hotel Dieu, Dept Hematol, Hotel Dieu, France

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Hematol, Amsterdam, Netherlands

[8] Univ Calif San Francisco, San Francisco, CA USA

[9] Ctr Hosp Univ Toulouse, Serv Hematol, Toulouse, France

[10] Univ Lille, Serv Hematol, CHU Lille, Hop Huriez, Lille, France

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[12] Univ Hosp Heidelberg, GMMG Study Grp, Dept Internal Med, Heidelberg, Germany

[13] Royal Wolverhampton NHS Trust, Wolverhampton, W Midlands, England

[14] Wolverhampton Univ, CRN West Midlands, NIHR, Wolverhampton, W Midlands, England

[15] Hop Haut Leveque, Univ Hosp, Dept Hematol, Bordeaux, France

[16] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[17] Sorbonne Univ, Hop St Antoine, Paris, France

[18] INSERM, UMRS938, Paris, France

[19] Vejle Hosp & Univ Southern Denmark, Vejle, Denmark

[20] Univ Southern Denmark, Odense, Denmark

[21] Univ Leeds, Leeds Inst Clin Trials Res, Canc Res UK Clin Trials Unit, Leeds, W Yorkshire, England

[22] CHU Poitiers, Hematol, PRC, Poitiers, France

[23] Univ Melbourne, St Vincents Hosp Melbourne, Melbourne, Vic, Australia

[24] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada

[25] Janssen Res Dev LLC, Lower Gwynedd Township, PA USA

[26] Mayo Clin, Rochester, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-324

引用

页码：S221 / S221

页数：1

共 50 条

[41] Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
Wang, Yan
Liu, Yuan-Fang
Jin, Shi-Wei
Tao, Yi
Zhang, Wei-Ping
Chen, Jian-Lin
Jiang, Song-Fu
Mi, Jian-Qing
SCIENTIFIC REPORTS, 2025, 15 (01):
[42] All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
Dimopoulos, Meletios A.
Grosicki, Sebastian
Jedrzejczak, Wieslaw W.
Nahi, Hareth
Gruber, Astrid
Hansson, Markus
Gupta, Neeraj
Byrne, Catriona
Labotka, Richard
Teng, Zhaoyang
Yang, Huyuan
Grzasko, Norbert
Kumar, Shaji
EUROPEAN JOURNAL OF CANCER, 2019, 106 : 89 - 98
[43] A glimpse into transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: carinae study
de Arriba de la Fuente, Felipe
Hernandez Garcia, Miguel Teodoro
Soler Campos, Juan Alfons
Herraez Rodriguez, Susana
Jose Moreno, Ma
Conzalez Pardo, Miriam
Gironella Mesa, Mercedes
Casanova Espinosa, Maria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S143 - S144
[44] Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: CARINAE study
Casanova Espinosa, Maria
Hernandez Garcia, Miguel Teodoro
Soler Campos, Juan Alfons
Herraez Rodriguez, Susana
Moreno Belmonte, Maria Jose
Gonzalez-Pardo, Miriam
Gironella Mesa, Mercedes
de Arriba de la Fuente, Felipe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S93 - S94
[45] Three Drug Regimens for Newly Diagnosed Multiple Myeloma Transplant-Ineligible Elderly Patients - a Systematic Review
Siddiqui, Abdul Aziz
Khan, Kazi Najamus-saqib
Farooqui, Arafat Ali
Farooqi, Muhammad Saad
Tariq, Muhammad Junaid
Anwer, Faiz
BLOOD, 2019, 134
[46] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
Kumar, Shaji K.
Moreau, Philippe
Bahlis, Nizar Jacques
Facon, Thierry
Plesner, Torben
Orlowski, Robert Z.
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Krevvata, Maria
Carson, Robin
Borgsten, Fredrik
Usmani, Saad
BLOOD, 2022, 140 : 10150 - 10153
[47] Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain: The CARINAE Study
de la Fuente, Felipe de Arriba
Mesa, Mercedes Gironella
Garcia, Miguel Teodoro Hernandez
Campos, Juan Alonso Soler
Rodriguez, Susana Herraez
Belmonte, Maria Jose Moreno
Lopez, Teresa Regueiro
Gonzalez-Pardo, Miriam
Espinosa, Maria Casanova
PHARMACEUTICALS, 2024, 17 (10)
[48] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study
Kumar, S. K.
Moreau, P.
Bahlis, N.
Facon, T.
Plesner, T.
Orlowski, R. Z.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Weisel, K.
Raje, N.
Tiab, M.
Macro, M.
Frenzel, L.
Leleu, X.
Wang, G.
Krevvata, M.
Carson, R.
Borgsten, F.
Usmani, S. Z.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 183 - 184
[49] Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)
Orlowski, Robert
Facon, Thierry
Kumar, Shaji
Plesner, Torben
Moreau, Philippe
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher
Weisel, Katja
Mace, Joseph
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Ahmadi, Tahamtan
Wang, Jianping
Van Rampelbergh, Rian
Uhlar, Clarissa
Tromp, Brenda
Delioukina, Maria
Vermeulen, Jessica
Usmani, Saad
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S424 - S425
[50] Daratumumab plus Lenalidomide/ dexamethasone in transplant-neligible patients with newly diagnosed multiple myeloma: MAIA update
Basu, Supratik
Kumar, Shaji K.
Moreau, Philippe
Bahlis, Nizar
Facon, Thierry
Plesner, Torben
Orlowski, Robert Z.
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Krevvata, Maria
Borgsten, Fredrik
Usmani, Saad Z.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 17 - 18

← 1 2 3 4 5 →